Apply This IPO

Best Margin

Zero Brokerage

24*7 Customer Support.

Fastest mobile support

---

Apply with Angel One

Apply with Zerodha

Pre-Apply with Upstox

Concord Biotech Limited IPO Review

Concord Biotech Limited was incorporated in 2000 and was engaged in a biopharma firm, a top global name in crafting fermentation-based APIs for immunosuppressants and oncology, holding a strong market position by volume. Their reach spans 70+ countries, including regulated markets. Concord Biotech Limited is a science-focused biopharmaceutical company. They make Active Pharmaceutical Ingredients (API) using fermentation, and semi-synthesis and also create finished medicines.
Their sales team covers 20 states and five union territories in India. They're also in the contract manufacturing business (CDMO), providing immunosuppressants within India. Their immunosuppressant products, made in facilities approved by international regulators like the US FDA, are sent to the US and several regions in Asia, Africa, and Latin America through distributor partnerships. Their Strengths are Established presence across complex fermentation, Global leadership in immunosuppressant APIs along with a wide spectrum, scaled manufacturing facilities with a consistent regulatory compliance track record, Diversified global customer base with long-standing relationships.

Concord Biotech Limited Products and Services

Concord Biotech Limited products and services are bio-pharmaceutical APIs using fermentation and semi-synthesis, focusing on immunosuppressants, oncology, and anti-infectives. They also make formulations for critical care, including immunosuppressants, nephrology drugs, and anti-infective drugs. APIs are like powerful medicine ingredients that can prevent or cure diseases. Their focus is on expanding Their immunosuppressant API collection, which will play a significant role in Their API business's growth. Alongside this, they’re striving to boost API sales in various medical fields beyond immunosuppressants.

Taking advantage of Their API expertise, they ventured into formulations in 2016. In India, they offer 27 brands of medicines including immunosuppressants, nephrology drugs, and critical care anti-infective drugs. This move leverages Their backward integration advantages.

Financial Overview

An Indian biopharmaceutical company with unique products. While FY22 saw a profit decline, the company achieved revenue growth in the past three fiscal years. A biopharmaceutical company based in India specializing in distinctive products. Despite a profit decrease in FY22, the company experienced revenue expansion over the last three fiscal years. Well informed all the details, Investors may think to apply for this IPO.